Publications by authors named "James B Aggen"

Claim this Profile
T
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors.
Shilpa Singh, Catherine E Gleason, Min Fang, Yasmin N Laimon, Vishal Khivansara, James B Aggen

Nature· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity.
Andrew T Bockus, Siegfried S F Leung, Breena Fraga-Walton, Miguel P Baldomero, Luis Hernandez, James B Aggen

J Med Chem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity.
Shilpa Singh, Catherine E Gleason, Min Fang, Yasmin N Laimon, Vishal Khivansara, James B Aggen

bioRxiv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors.
G Leslie Burnett, Yu C Yang, James B Aggen, Jennifer Pitzen, Micah K Gliedt

J Med Chem· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.
Bianca J Lee, Jacob A Boyer, G Leslie Burnett, Arun P Thottumkara, Nidhi Tibrewal, James B Aggen

Nat Chem Biol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.
Bianca J Lee, Jacob A Boyer, G Leslie Burnett, Arun P Thottumkara, Nidhi Tibrewal, James B Aggen

Nat Chem Biol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.
Bianca J Lee, Jacob A Boyer, G Leslie Burnett, Arun P Thottumkara, Nidhi Tibrewal, James B Aggen

Nat Chem Biol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety.
Frederick Cohen, James B Aggen, Logan D Andrews, Zahra Assar, Jen Boggs

ChemMedChem· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compound design guidelines for evading the efflux and permeation barriers of Escherichia coli with the oxazolidinone class of antibacterials: Test case for a general approach to improving whole cell Gram-negative activity.
Andrew Spaulding, Khuloud Takrouri, Pornachandran Mahalingam, Dillon C Cleary, Harold D Cooper, James B Aggen

Bioorg Med Chem Lett· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress against Escherichia coli with the Oxazolidinone Class of Antibacterials: Test Case for a General Approach To Improving Whole-Cell Gram-Negative Activity.
Khuloud Takrouri, Harold D Cooper, Andrew Spaulding, Paola Zucchi, Bilyana Koleva, James B Aggen

ACS Infect Dis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity modulation, resistance enzyme evasion, and A-site X-ray structure of broad-spectrum antibacterial neomycin analogs.
Juan Pablo Maianti, Hiroki Kanazawa, Paola Dozzo, Rowena D Matias, Lee Ann Feeney, James B Aggen

ACS Chem Biol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multivalent design of long-acting β(2)-adrenoceptor agonists incorporating biarylamines.
John R Jacobsen, James B Aggen, Timothy J Church, Uwe Klein, Juergen W Pfeiffer

Bioorg Med Chem Lett· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.
Andrew M K Pennell, James B Aggen, Subhabrata Sen, Wei Chen, Yuan Xu

Bioorg Med Chem Lett· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue.
Stephen Hanessian, Alexandre Giguère, Justyna Grzyb, Juan Pablo Maianti, Oscar M Saavedra, James B Aggen

ACS Med Chem Lett· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models.
Noe Reyes, James B Aggen, Corwin F Kostrub

Antimicrob Agents Chemother· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and spectrum of the neoglycoside ACHN-490.
James B Aggen, Eliana S Armstrong, Adam A Goldblum, Paola Dozzo, Martin S Linsell

Antimicrob Agents Chemother· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
Andrea Endimiani, Kristine M Hujer, Andrea M Hujer, Eliana S Armstrong, Yuvraj Choudhary, James B Aggen

Antimicrob Agents Chemother· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multivalent approach to drug discovery for novel antibiotics.
Daniel D Long, James B Aggen, Burton G Christensen, J Kevin Judice, Sharath S Hegde

J Antibiot (Tokyo)· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the positional attachment of glycopeptide/beta-lactam heterodimers.
Daniel D Long, James B Aggen, Jason Chinn, Seok-Ki Choi, Burton G Christensen

J Antibiot (Tokyo)· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A central strategy for converting natural products into fluorescent probes.
Matthew D Alexander, Michael D Burkart, Michael S Leonard, Padma Portonovo, Bo Liang, James B Aggen

Chembiochem· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linearized and truncated microcystin analogues as inhibitors of protein phosphatases 1 and 2A.
Brian M Gulledge, James B Aggen, A Richard Chamberlin

Bioorg Med Chem Lett· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microcystin analogues comprised only of Adda and a single additional amino acid retain moderate activity as PP1/PP2A inhibitors.
Brian M Gulledge, James B Aggen, Hugo Eng, Khuloud Sweimeh, A Richard Chamberlin

Bioorg Med Chem Lett· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis